Strong decrease in streptomycin-resistance and absence of XDR 12 years after the reorganization of the National Tuberculosis Control Program in the Central Region of Cameroon

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Sidze, Larissa Kamgue ^a,g,i   Tekwu, Emmanuel Mouafo ^a,g,i   Kuaban, Christopher ^b   Assam, Jean Paul Assam ^a,i   Tedom, Jean Claude ^a,i   Eyangoh, Sara ^c   Fouda, François Xavier ^d   Nolna, Désiré ^e   Ntoumi, Francine ^f,g,i   Frank, Matthias ^g,h,i   Beng, Véronique N Penlap ^a,i  

^a UNIVERSITY OF YAOUNDÉ I   (Cameroon)

^b Jamot Hospital   (Cameroon)

^c CENTRE PASTEUR DU CAMEROUN   (Cameroon)

^d Mbalmayo District Hospital   (Cameroon)

^e National Tuberculosis Control Programme   (Cameroon)

^f UNIVERSITÉ MARIEN NGOUABI   (Congo)

^g UNIVERSITY OF TÜBINGEN   (Germany)

^h Deutsches Zentrum für Infektionsforschung DZIF   (Germany)

ⁱ Central African Network for Tuberculosis AIDS HIV and Malaria (CANTAM)   (Congo)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; KANAMYCIN; OFLOXACIN; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM IDENTIFICATION; CAMEROON; CROSS-SECTIONAL STUDY; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; FEMALE; FOLLOW UP; HEALTH CARE POLICY; HEALTH PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RATE; INFECTION RISK; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MONOTHERAPY; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PREVALENCE; RISK FACTOR; SHORT COURSE THERAPY; SPUTUM CULTURE; TUBERCULOSIS CONTROL; YOUNG ADULT; DRUG EFFECTS; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; GENETICS; HEALTH SURVEY; MICROBIAL SENSITIVITY TEST; MIDDLE AGED; MULTIDRUG RESISTANCE; PUBLIC HEALTH; SOCIOECONOMICS; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTITUBERCULAR AGENTS; CAMEROON; CROSS-SECTIONAL STUDIES; DRUG RESISTANCE, MULTIPLE, BACTERIAL; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; NATIONAL HEALTH PROGRAMS; POPULATION SURVEILLANCE; RISK FACTORS; SOCIOECONOMIC FACTORS; STREPTOMYCIN; YOUNG ADULT;

EID: 84902491281     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0098374     Document Type: Article

References (28)

1. World Health Organization (2012) Global tuberculosis report 2012. Geneva: Library Cataloguing-in-Publication Data; World Health Organisation, WHO/HTM/TB/2012.62.
2. Frieden TR, Fujiwara PI, Washko RM, Hamburg MA (1995) Tuberculosis in New York City - turning the tide. N Engl J Med 333: 229-233.
3. DeRiemer K, Garcia-Garcia L, Bobadilla-del-Valle M, Palacios-Martinez M, Martinez-Gamboa A, et al. (2005) Does DOTS work in populations with drug-resistant tuberculosis? Lancet 365: 1239-1245. (Pubitemid 40469656)
4. Kam KM, Yip CW (2001) Surveillance of Mycobacterium tuberculosis drug resistance in Hong Kong, 1986-1999, after the implementation of directly observed treatment. Int J Tuberc Lung Dis 5: 815-823. (Pubitemid 32843674)
5. Kam KM, Yip CW (2004) Surveillance of Mycobacterium tuberculosis susceptibility to second-line drugs in Hong Kong, 1995-2002, after the implementation of DOTS-plus. Int J Tuberc Lung Dis 8: 760-766. (Pubitemid 38747153)
6. Cauthen GM, Dooley SW, Onorato IM, Ihle WW, Burr JM, et al. (1996) Transmission of Mycobacterium tuberculosis from tuberculosis patients with HIV infection or AIDS. Am J Epidemiol 144: 69-77. (Pubitemid 26225289)
7. Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, et al. (2006) Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 368: 1575-1580. (Pubitemid 44780738)
8. Bercion R, Kuaban C (1997) Initial resistance to antituberculosis drugs in Yaounde, Cameroon in 1995. Int J Tuberc Lung Dis 1: 110-114. (Pubitemid 127509665)
9. Kuaban C, Bercion R, Jifon G, Cunin P, Blackett KN (2000) Acquired anti-tuberculosis drug resistance in Yaounde, Cameroon. Int J Tuberc Lung Dis 4: 427-432. (Pubitemid 30256845)
10. Keugoung B, Buve A, Nolna D, Macq J, Meli J, et al. (2013) Thirty years of tuberculosis control in Cameroon: alternating "vertical'" and "horizontal" health care delivery systems. Rev Epidémiol Sante Publique 61: 129-138.
11. Degommier J (1957) Nouvelle technique de coloration des bacilles tuberculeux pour la recherche en fluorescence. Ann Inst Pasteur: 692-694.
12. Grosset J, Boisvert H, Truffot-Pernot C (1990) Mycobacteries. In: Leminor L, Veron M, editors. Bacteriologie médicale. Paris: Flammarion. 965-1117.
13. Canetti G, Fox W, Khomenko A, Mahler HT, Menon NK, et al. (1969) Advances in techniques of testing mycobacterial drug sensitivity, and the use of sensitivity tests in tuberculosis control programmes. Bull World Health Organ 41: 21-43.
14. Chode TM (1989) The role of bacteriological surveys in the National Tuberculosis and Leprosy Programme in Tanzania. Bull Int Union Tuberc Lung Dis 64: 37-39.
15. World Health Organization (2008) Antituberculosis drugs resistance in the world. Fourth Global Report. The WHO/IUATLD Global Project on Antituberculosis Drug Resistance Surveillance 2002-2007. Geneva: World Health Organization. WHO/HTM/TB/2008.394.
16. Chaulet P, Boulahbal F, Grosset J (1995) Surveillance of drug resistance for tuberculosis control: why and how? Tuber Lung Dis 76: 487-492. (Pubitemid 26008703)
17. Assam-Assam JP, Penlap VB, Cho-Ngwa F, Tedom JC, Ane-Anyangwe I, et al. (2011) Mycobacterium tuberculosis complex drug resistance pattern and identification of species causing tuberculosis in the West and Centre regions of Cameroon. BMC Infect Dis 11: 94.
18. Tantchou J (2007) Epidémie et politique en Afrique. Maladie du sommeil et tuberculose au Cameroun. l'Harmattan. 267.
19. Meriki HD, Tufon KA, Atanga PN, Ane-Anyangwe IN, Anong DN, et al. (2013) Drug resistance profiles of Mycobacterium tuberculosis complex and factors associated with drug resistance in the Northwest and Southwest Regions of Cameroon. PloS one 8: e77410.
20. Takiff H, Guerrero E (2011) Current prospects for the fluoroquinolones as firstline tuberculosis therapy. Antimicrob Agents Chemother 55: 5421-5429.
21. Zhang Z, Lu J, Wang Y, Pang Y, Zhao Y (2014) Prevalence and molecular characterization of fluoroquinolone-resistant Mycobacterium tuberculosis isolates in China. Antimicrob Agents Chemother 58: 364-369.
22. Noeske J, Voelz N, Fon E, Abena Foe JL (2012) Early results of systematic drug susceptibility testing in pulmonary tuberculosis retreatment cases in Cameroon. BMC Res Notes 5: 160.
23. Kuaban C, Bercion R, Noeske J, Cunin P, Nkamsse P, et al. (2000) Anti-tuberculosis drug resistance in the West Province of Cameroon. Int J Tuberc Lung Dis 4: 356-360. (Pubitemid 30194112)
24. Sangare L, Diande S, Kouanda S, Dingtoumda BI, Mourfou A, et al. (2011) Mycobacterium tuberculosis drug-resistance in previously treated patients in Ouagadougou, Burkina Faso. Ann Afr Med 9: 15-19.
25. Sidze KL, Tekwu EM, Kuaban C, Assam-Assam JP, Tedom JC, et al. (2013) Estimates of Genetic Variability of Mycobacterium tuberculosis Complex and Its Association with Drug Resistance in Cameroon. Adv Infect Dis 3: 55-59.
26. Caws M, Thwaites G, Stepniewska K, Nguyen TN, Nguyen TH, et al. (2006) Beijing genotype of Mycobacterium tuberculosis is significantly associated with human immunodeficiency virus infection and multidrug resistance in cases of tuberculous meningitis. J Clin Microbiol 44: 3934-3939. (Pubitemid 44737232)
27. Sharma SK, Mohan A (2004) Multidrug-resistant tuberculosis. Indian J Med Res 120: 354-376. (Pubitemid 39504472)
28. Dolgin E (2010) African networks launch to boost clinical trial capacity. Nat Med 16: 8.